Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Glossary Glossary

HIV JournalView


  • Top 10 Research Publications in HIV Care of 2005 (January 2006)
    Thousands of HIV-related studies were published in 2005, but only a handful heralded fundamental changes in the way we approach HIV screening and treatment; David Wohl, M.D., recaps these critical studies and explains their significance in this issue of HIV JournalView.
    To read PDF, click here.
    From TheBodyPRO.com
  • HIV JournalView (December 2005)
    Mark Holodniy, M.D., discusses recently published studies on partial HIV treatment interruption, lopinavir/ritonavir monotherapy, hyperlipidemia management strategies, coadministration of didanosine + tenofovir, the success of treatment access programs in the developing world, and the protective benefits of male circumcision.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (November 2005)
    Margaret Hoffman-Terry, M.D., analyses the findings of recently published studies on the relationship (or lack thereof) between lipoatrophy and lipohypertrophy, shedding of nevirapine-resistant virus in breast milk, neuropsychiatric impairment in HIV/hepatitis C-coinfected patients, and the importance of using CD4+ cell percentage in treatment initiation decisions.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (September 2005)
    David Wohl, M.D., reviews recently published research on the need (or lack thereof) to switch regimens in patients with low-level viremia, a dementia test for resource-poor areas, the growing epidemic of obesity among HIV-infected patients, the link between insulin resistance and NRTIs (not PIs!), and a final word on the whole valproic acid/"HIV cure" kerfuffle.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (July/August 2005)
    David Wohl, M.D., reviews many newly published studies, including research on the role of HAART in hypertension, the interaction between efavirenz (EFV, Sustiva, Stocrin) and statins, the best way to manage dyslipidemia in HAART patients, and several new approaches to HIV therapeutics.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (May/June 2005)
    Margaret Hoffman-Terry, M.D., examines recent studies on a range of HIV-related health problems, including bone and joint problems, the long-term health risks of tenofovir (TDF, Viread), the neurological effects of efavirenz (EFV, Sustiva, Stocrin) and new insight into the treatment of people who are coinfected with HIV and hepatitis C.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (April 2005)
    Mark Holodniy, M.D., analyzes recently published research on poly-L-lactic acid for facial wasting, resistance testing, interactions between antiretrovirals and natural health products, and several other topical issues in HIV disease management.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (February/March 2005)
    David Wohl, M.D., assesses the significance of recent research on predictors of HIV drug resistance, cost-effectiveness of HIV screening, contraindication of fosamprenavir lopinavir/ritonavir, incidence of NNRTI-related rash and an update on metabolic complications.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 Research Reports of 2004 (January 2005)
    David Wohl, M.D., reviews the top 10 published research reports of 2004.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (December 2004)
    Ben Young, M.D., Ph.D., analyzes a bevy of recently published studies and opinions on HIV treatment; among the topics he examines are when to start treatment, when to pause it and how effective it is on both edges of the age spectrum -- infants and patients over 50; also included is an examination of hepatitis A vaccination in HIV-infected patients.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (October/November 2004)
    David Wohl, M.D., reviews a quintet of recently published studies on mortality, HIV treatment initiation, the tenofovir-associated K65R mutation, viral loads and sexual risk behavior, and cesarean delivery in HIV/hepatitis C-coinfected patients.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (September 2004)
    Mark Holodniy, M.D., F.A.C.P., C.I.C., examines 7 recently published studies, including new research on sperm washing, enfuvirtide (T-20, Fuzeon) resistance mutations and two experimental lipodystrophy treatments: suction-assisted lipectomy and exogenous growth hormone.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (August 2004)
    David Wohl, M.D., examines the therapeutic effects of acetyl-L-carnitine on distal peripheral neuropathy; the growing prevalence of HIV drug resistance, and the lack of corresponding impact on CD4+ cell count and viral load; the use of niacin as a safe alternative to statins for hyperlipidemia; and risk factors associated with the widely reported HIV outbreak in North Carolina among black, college-age men who have sex with men.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (July 2004)
    Keith Henry, M.D., analyzes 12 published studies on a wide array of topics, including the risks of sexual transmission during acute infection; the prospects of successful treatment after failing a protease inhibitor-based HAART regimen; and a possible explanation for why the enigmatic GBV-C slows HIV progression.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (June 2004)
    David Wohl, M.D., analyzes several recently published studies on the occurrence, impact and transmission of drug-resistant HIV and resistance testing.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (May 2004)
    David Wohl, M.D., analyzes newly published research on the clinical implications of viral load "blips," the improvement of lipoatrophy through antiretroviral switching, the use of HAART to treat cognitive impairment and the ramifications of ACTG 5095.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (April 2004)
    David Wohl, M.D., analyzes newly published research on the impact of GBV-C on HIV progression, long-term data on lopinavir/ritonavir, the use of lipid screening by healthcare providers and updated figures on heterosexual HIV transmission in the United States.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 Research Reports of 2003 (February 2004)
    David Wohl, M.D., reviews the top 10 published research reports of 2003.
    To read PDF, click here.
    From TheBodyPRO.com

  • < Previous | 1 | 2


  
  • Email Email
  • Glossary Glossary
Advertisement